Halozyme Therapeutics’ (HALO) “Buy” Rating Reiterated at Benchmark

Halozyme Therapeutics (NASDAQ:HALO)‘s stock had its “buy” rating restated by equities researchers at Benchmark in a report released on Thursday,Benzinga reports. They presently have a $75.00 price objective on the biopharmaceutical company’s stock. Benchmark’s target price points to a potential upside of 29.87% from the stock’s previous close.

Several other research firms have also weighed in on HALO. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. HC Wainwright upped their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday. JMP Securities upped their price target on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Finally, Wells Fargo & Company decreased their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $62.78.

Halozyme Therapeutics Stock Up 0.5 %

Halozyme Therapeutics stock opened at $57.75 on Thursday. The firm has a market capitalization of $7.11 billion, a PE ratio of 16.84, a P/E/G ratio of 0.44 and a beta of 1.25. The company’s 50-day moving average is $53.46 and its 200-day moving average is $54.62. Halozyme Therapeutics has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. Sell-side analysts anticipate that Halozyme Therapeutics will post 4.72 earnings per share for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the transaction, the director now owns 43,611 shares in the company, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. RPg Family Wealth Advisory LLC acquired a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $1,886,000. Segall Bryant & Hamill LLC lifted its holdings in shares of Halozyme Therapeutics by 16.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after acquiring an additional 49,856 shares during the period. Retirement Systems of Alabama lifted its holdings in shares of Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after acquiring an additional 74,173 shares during the period. South Street Advisors LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $9,812,000. Finally, Shaker Investments LLC OH lifted its holdings in shares of Halozyme Therapeutics by 12.3% during the 4th quarter. Shaker Investments LLC OH now owns 75,326 shares of the biopharmaceutical company’s stock worth $3,601,000 after acquiring an additional 8,249 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.